Role of Interleukin-6 Gene Variants in the Development of Oral Squamous Cell Carcinoma

TEKCAN, AKIN; Yigit, Serbulent; Gumusay, Ozge; Nursal, Ayse Feyda; DAGMURA, HASAN; KURUCA, Nilufer

doi:10.5505/tjo.2022.3624

Role of Interleukin-6 Gene Variants in the Development of Oral Squamous Cell Carcinoma

Özge GÜMÜŞAY, (Gaziosmanpaşa Üniversitesi, Tıp Fakültesi, Onkoloji Anabilim Dalı, Tokat,Türkiye)

Serbülent YİĞİT, (Ondokuz Mayıs Üniversitesi, Veteriner Fakültesi, Genetik Bölümü, Samsun, Türkiye)

Ayşe Feyda NURSAL, (Hitit Üniversitesi, Tıp Fakültesi, Tıbbi Genetik Anabilim Dalı, Çorum, Türkiye)

Akın TEKCAN, (Amasya Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji Anabilim Dalı, Amasya, Türkiye)

Hasan DAĞMURA, (Bezmialem Üniversitesi, Tıp Fakültesi, Genel Cerrahi Anabilim Dalı, İstanbul, Türkiye)

Nilüfer KURUCA (Ondokuz Mayıs Üniversitesi, Veteriner Fakültesi, Patoloji Anabilim Dalı, Samsun, Türkiye)

Türk Onkoloji Dergisi

1 0

Yıl: 2022 Cilt: 37 Sayı: 4 Sayfa Aralığı: 371 - 378 Metin Dili: İngilizce DOI: 10.5505/tjo.2022.3624 İndeks Tarihi: 26-05-2023

Role of Interleukin-6 Gene Variants in the Development of Oral Squamous Cell Carcinoma

Öz:

OBJECTIVE Oral squamous cell carcinoma (OSCC), with its low survival rates and increasing incidence, is due to various etiological factors including environmental, genetic, and epigenetic changes. Interleukin 6 (IL- 6) is a cytokine with both pro- and anti-inflammatory effects. Therefore, we investigated the possible association of the IL-6 gene variants with risk for OSCC in a Turkish cohort. METHODS This study included 42 patients with OSCC and 110 age-and gender-matched healthy controls. Three variants (-174G/C [rs1800795], -572G/C (rs1800796), and -597G/A [rs1800797]) in the IL-6 pro- moter region were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. RESULTS There was a significant difference in the genotype and allele frequencies of the IL-6 -174G/C vari- ant between OSCC patients and controls. While the IL-6 -174G/C G/C genotype was higher in the patient group than in the control group, the G/G and C/C genotypes were lower in the patients compared to the control group (p=0.016, OR:0.653, 95% CI: 0.38-1.11). The genotype and allele dis- tributions of -572G/C and -597G/A variants of the IL-6 gene were not statistically different between OSCC patients and the control group. CONCLUSION Our current investigation is focused on the role of variants of IL-6 gene on OSCC. To the best of our knowledge, this study is the first study to evaluate the genotype and allele frequencies of IL-6 -174G/C, -572G/C, and 597G/A variants in patients with OSCC in a Turkish population. The results support that the IL-6 -174G/C variant may play an important role in susceptibility to OSCC in our population.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Sun Y, Liu N, Guan X, Wu H, Sun Z, Zeng H. Im- munosuppression induced by chronic inflammation and the progression to oral squamous cell carcinoma. Mediators Inflamm 2016;2016:5715719.
2. Vigneswaran N, Williams MD. Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac Surg Clin North Am 2014;26(2):123–41.
3. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002;13:357–68.
4. Jawa RS, Anillo S, Huntoon K, Baumann H, Kulaylat M. Interleukin-6 in surgery, trauma, and critical care part II: clinical implications. Interleukin-6 in surgery, trauma, and critical care part II: clinical implications. J Intensive Care Med 2011;26(2):73–87.
5. Li F, Xu J, Zheng J, Sokolove J, Zhu K, Zhang Y, et al. Association between interleukin-6 gene polymor- phisms and rheumatoid arthritis in Chinese Han pop- ulation: a case-control study and a meta-analysis. Sci Rep 2014;4:5714.
6. Zhai K, Yang Y, Gao ZG, Ding J. Interleukin-6-174G>C gene promoter polymorphism and prognosis in pa- tients with cancer. Oncotarget 2017;8(27):44490–97.
7. Tseng LH, Chen PJ, Lin MT, Singleton K, Martin EG, Yen AH, et al. Simultaneous genotyping of single nu- cleotide polymorphisms in the IL-6, IL-10, TNFalpha and TNFbeta genes. Tissue Antigens 2002;59:280–86.
8. Kim MM, Califano JA. Molecular pathology of head and neck cancer. Int J Cancer 2004;112:545–54.
9. Choudhary MM, France TJ, Teknos TN, Kumar P. In- terleukin-6 role in head and neck squamous cell car- cinoma progression. World J Otorhinolaryngol Head Neck Surg 2016;2(2):90–7.
10. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374(Pt 1):1–20.
11. Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol 2016;37:11553–72.
12. Chen MF, Chen PT, Lu MS, Lin PY, Chen WC, Lee KD. IL-6 expression predicts treatment response and out- come in squamous cell carcinoma of the esophagus. Molecular cancer 2013;12(1):26.
13. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 sig- naling pathway in targeted therapy for cancer. Cancer treatment reviews 2012;38(7):904–10.
14. Lippman SM, Hong WK. Molecular markers of the risk of oral cancer. N Engl J Med 2001;344:1323–26.
15. Mehrotra R, Gupta A, Singh M, Ibrahim R. Application of cytology and molecular biology in diagnosing prema- lignant or malignant oral lesions. Mol Cancer 2006;5:11.
16. Wu JY, Yi C, Chung HR, Wang DJ, Chang WC, Lee SY, et al. Potential biomarkers in saliva for oral squamous cell carcinoma. Oral Oncol 2010;46:226–31.
17. Feng XY, Li JH, Li JZ, Han ZX, Xing RD. Serum SCCA, Cyfra 21-1, EGFR and Cyclin D1 levels in patients with oral squamous cell carcinoma. Int J Biol Markers 2010;25(2):93–8.
18. Cohen RF, Contrino J, Spiro JD, Mann EA, Chen LL, et al. Interleukin-8 expression by head and neck squa- mous cell carcinoma. Arch Otolaryngol Head Neck Surg 1995;121(2):202–9.
19. Lee LT, Wong YK, Hsiao HY, Wang YW, Chan MY, Chang KW. Evaluation of saliva and plasma cytokine biomarkers in patients with oral squamous cell carci- noma. Int J Oral Maxillofac Surg 2018;47(6):699–707.
20. Alevizos I, Mahadevappa M, Zhang X, Ohyama H, Kohno Y, Posner M, et al. Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysis. Oncogene 2001;20(43):6196–204.
21. Wang YF, Chang SY, Tai SK, Li WY, Wang LS. Clinical significance of interleukin-6 and interleukin-6 recep- tor expressions in oral squamous cell carcinoma. Head Neck 2002;24(9):850–58.
22. Chen CJ, Sung WW, Lin YM, Chen MK, Lee CH, Lee H, et al. Gender difference in the prognostic role of in- terleukin 6 in oral squamous cell carcinoma. Plos One 2012;7(11):e50104.
23. Banday MZ, Balkhi HM, Sameer AS, Chowdri NA, Haq E. Strong association of interleukin-6 –174G/C promoter single nucleotide polymorphism with a decreased risk of colorectal cancer in ethnic Kash- miri population: A case control study. Tumour Biol 2017;39(3):1010428317695940.
24. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin-6 transcrip- tional regulation. J Biol Chem 2000;275(24):18138–44.
25. Savage SA, Abnet CC, Haque K, Mark SD, Qiao YL, Dong ZW, et al. Polymorphisms in interleukin − 2, − 6, and − 10 are not associated with gastric cardia or esophageal cancer in a high-risk Chinese population. Cancer Epidemiol Biomarkers Prev 2004;13(9):1547–9.
26. Singh PK, Chandra G, Bogra J, Gupta R, Kumar V, Jain A, et al. Association of interleukin-6 genetic polymor- phisms with risk of OSCC in Indian population. Meta Gene 2015;4:142–51.
27. Vairaktaris E, Yiannopoulos A, Vylliotis A, Yapijakis C, Derka S, Vassiliou S, et al. Strong association of interleukin-6 -174 G>C promoter polymorphism with increased risk of oral cancer. J Biol Markers 2006;21:246–50.
28. Zafar M, Hadi NI, Baig S, Zehra N. Association be- tween Interleukin 6 gene polymorphism and human papilloma virus infection in oral squamous cell carci- noma patients. BJMMR 2015;10(6):1–9.
29. Hsu HJ, Yang YH, Shieh TY, Chen CH, Kao YH, Yang CF, et al. Role of cytokine gene (interferon-γ, trans- forming growth factor-β1, tumor necrosis factor-α, interleukin-6, and interleukin-10) polymorphisms in the risk of oral precancerous lesions in Taiwanese. Kaohsiung J Med Sci 2014;30(11):551–58.
30. Gaur P, Mittal M, Mohanti B, Das S. Functional vari- ants of IL4 and IL6 genes and risk of tobacco-related oral carcinoma in high-risk Asian Indians. Oral Dis 2011;17(7):720–6.
31. Shin KK, Jang Y, Koh SJ, Chae JS, Kim OY, Park S, et al. Influence of the IL-6 -572C>G polymorphism on inflammatory markers according to cigarette smoking in Korean healthy men. Cytokine 2007;39(2):116–22.
32. Seow A, Ng DP, Choo S, Eng P, Poh WT, Ming T, et al. Joint effect of asthma/atopy and an IL-6 gene polymor- phism on lung cancer risk among lifetime non-smok- ing Chinese women. Carcinogenesis 2006;27:1240–44.
33. Zhang Z, Chen Z, Chen D, Lin Y, Jiang Y, Wang Q. As- sociation between IL-6-572 C/G polymorphism and breast cancer susceptibility. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2016;32(12):1667–70.
34. Liu S, Qiu X, Zeng X, Bai H, Bei C, Yang Y. Relation- ship between IL6-572G/C polymorphism and hepato- cellular carcinoma in men. Zhonghua Gan Zang Bing Za Zhi 2012;20(6):463–67.
35. Gatti LL, Burbano RR, Zambaldi-Tunes M, de-Lábio RW, de Assumpção PP, de Arruda Cardoso-Smith M, et al. Interleukin-6 polymorphisms, Helicobacter py- lori infection in adult Brazilian patients with chronic gastritis and gastric adenocarcinoma. Arch Med Res 2007;38(5):551–5.
36. DeMichele A, Gray R, Horn M, Chen J, Aplenc R, Vaughan WP, et al. Host genetic variants in the inter- leukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer. Cancer Res 2009;69(10):4184–91.
37. Snoussi K, Strosberg AD, Bouaouina N, Ben Ahmed S, Chouchane L. Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma. Eur Cytokine Netw 2005;16(4):253–60.
38. Wilkening S, Hemminki K, Rudnai P, Gurzau E, Kop- pova K, Kumar R, et al. Case-control study in basal cell carcinoma of the skin: single nucleotide polymor- phisms in three interleukin promoters pre-analysed in pooled DNA. Br J Dermatol 2006;155(6):1139–44.
39. Gupta MK, Sagar N, Pant R, Banarjee M. Cytokine gene polymorphisms and their association with oral squamous cell carcinoma (OSCC): a North Indian study. EJPMR 2016:3(8):550–58.

APA	Gumusay O, Yigit S, Nursal A, TEKCAN A, DAGMURA H, KURUCA N (2022). Role of Interleukin-6 Gene Variants in the Development of Oral Squamous Cell Carcinoma. , 371 - 378. 10.5505/tjo.2022.3624
Chicago	Gumusay Ozge,Yigit Serbulent,Nursal Ayse Feyda,TEKCAN AKIN,DAGMURA HASAN,KURUCA Nilufer Role of Interleukin-6 Gene Variants in the Development of Oral Squamous Cell Carcinoma. (2022): 371 - 378. 10.5505/tjo.2022.3624
MLA	Gumusay Ozge,Yigit Serbulent,Nursal Ayse Feyda,TEKCAN AKIN,DAGMURA HASAN,KURUCA Nilufer Role of Interleukin-6 Gene Variants in the Development of Oral Squamous Cell Carcinoma. , 2022, ss.371 - 378. 10.5505/tjo.2022.3624
AMA	Gumusay O,Yigit S,Nursal A,TEKCAN A,DAGMURA H,KURUCA N Role of Interleukin-6 Gene Variants in the Development of Oral Squamous Cell Carcinoma. . 2022; 371 - 378. 10.5505/tjo.2022.3624
Vancouver	Gumusay O,Yigit S,Nursal A,TEKCAN A,DAGMURA H,KURUCA N Role of Interleukin-6 Gene Variants in the Development of Oral Squamous Cell Carcinoma. . 2022; 371 - 378. 10.5505/tjo.2022.3624
IEEE	Gumusay O,Yigit S,Nursal A,TEKCAN A,DAGMURA H,KURUCA N "Role of Interleukin-6 Gene Variants in the Development of Oral Squamous Cell Carcinoma." , ss.371 - 378, 2022. 10.5505/tjo.2022.3624
ISNAD	Gumusay, Ozge vd. "Role of Interleukin-6 Gene Variants in the Development of Oral Squamous Cell Carcinoma". (2022), 371-378. https://doi.org/10.5505/tjo.2022.3624

APA	Gumusay O, Yigit S, Nursal A, TEKCAN A, DAGMURA H, KURUCA N (2022). Role of Interleukin-6 Gene Variants in the Development of Oral Squamous Cell Carcinoma. Türk Onkoloji Dergisi, 37(4), 371 - 378. 10.5505/tjo.2022.3624
Chicago	Gumusay Ozge,Yigit Serbulent,Nursal Ayse Feyda,TEKCAN AKIN,DAGMURA HASAN,KURUCA Nilufer Role of Interleukin-6 Gene Variants in the Development of Oral Squamous Cell Carcinoma. Türk Onkoloji Dergisi 37, no.4 (2022): 371 - 378. 10.5505/tjo.2022.3624
MLA	Gumusay Ozge,Yigit Serbulent,Nursal Ayse Feyda,TEKCAN AKIN,DAGMURA HASAN,KURUCA Nilufer Role of Interleukin-6 Gene Variants in the Development of Oral Squamous Cell Carcinoma. Türk Onkoloji Dergisi, vol.37, no.4, 2022, ss.371 - 378. 10.5505/tjo.2022.3624
AMA	Gumusay O,Yigit S,Nursal A,TEKCAN A,DAGMURA H,KURUCA N Role of Interleukin-6 Gene Variants in the Development of Oral Squamous Cell Carcinoma. Türk Onkoloji Dergisi. 2022; 37(4): 371 - 378. 10.5505/tjo.2022.3624
Vancouver	Gumusay O,Yigit S,Nursal A,TEKCAN A,DAGMURA H,KURUCA N Role of Interleukin-6 Gene Variants in the Development of Oral Squamous Cell Carcinoma. Türk Onkoloji Dergisi. 2022; 37(4): 371 - 378. 10.5505/tjo.2022.3624
IEEE	Gumusay O,Yigit S,Nursal A,TEKCAN A,DAGMURA H,KURUCA N "Role of Interleukin-6 Gene Variants in the Development of Oral Squamous Cell Carcinoma." Türk Onkoloji Dergisi, 37, ss.371 - 378, 2022. 10.5505/tjo.2022.3624
ISNAD	Gumusay, Ozge vd. "Role of Interleukin-6 Gene Variants in the Development of Oral Squamous Cell Carcinoma". Türk Onkoloji Dergisi 37/4 (2022), 371-378. https://doi.org/10.5505/tjo.2022.3624